Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.42 |
| ▸ | TYMP | P19971 | 2/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.36 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.36 |
| ▸ | FUT6 | P51993 | 3/20 | 0.36 |
| ▸ | KRAS | P01116 | 4/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18769136 | 0.96 | TAS1R3 (0.41) | TAS1R3TAS1R1TYMPIMPDH2IMPDH1 | |
| SCHEMBL18759047 | 0.96 | TAS1R3 (0.43) | TAS1R3TAS1R1TYMPIMPDH2IMPDH1 | |
| SCHEMBL18769139 | 0.85 | TYMP (0.36) | TAS1R3TAS1R1TYMPHPGD | |
| SCHEMBL21184283 | 0.85 | TYMP (0.36) | TAS1R3TAS1R1TYMPHPGD | |
| SCHEMBL18759035 | 0.85 | TYMP (0.36) | TAS1R3TAS1R1TYMPHPGD | |
| SCHEMBL21163079 | 0.85 | TYMP (0.36) | TAS1R3TAS1R1TYMPHPGD | |
| SCHEMBL21171618 | 0.85 | TYMP (0.36) | TAS1R3TAS1R1TYMPHPGD | |
| SCHEMBL18759043 | 0.85 | TYMP (0.36) | TAS1R3TAS1R1TYMPHPGD | |
| SCHEMBL21475702 | 0.81 | TYMP (0.44) | TAS1R3TAS1R1TYMPIMPDH2IMPDH1 | |
| SCHEMBL25436741 | 0.80 | TYMP (0.53) | TAS1R3TAS1R1TYMPHPGDNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570388-B2 | Phosphate replacement MRNA cap analogs | MODERNATX, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10563195-B2 | Phosphate replacement mRNA cap analogs | MODERNATX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570388-B2 | Phosphate replacement MRNA cap analogs | RNGTT, RNMT, CPSF6 | TAS1R3 4252/4885TAS1R1 4606/4885TYMP 109/4885 |
| US-10563195-B2 | Phosphate replacement mRNA cap analogs | RNGTT, RNMT, CPSF6 | TAS1R3 4252/4885TAS1R1 4606/4885TYMP 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.